Promis

ProMIS Neurosciences to Present at 2021 Alzheimer’s Association International Conference

Retrieved on: 
Thursday, July 22, 2021
Branches of biology, Proteins, Biology, Amyloidosis, Neurological disorders, Structural proteins, Alzheimer's disease, Amyloid, Histopathology, TAR DNA-binding protein 43, Neurodegeneration, Promis

TORONTO and CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will give two presentations at the annual Alzheimers Association International Conference (AAIC) to be held July 26-30, 2021 in Denver, USA and online.

Key Points: 
  • TORONTO and CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will give two presentations at the annual Alzheimers Association International Conference (AAIC) to be held July 26-30, 2021 in Denver, USA and online.
  • ProMIS Chief Scientific Officer, Dr. Neil Cashman will give an oral presentation entitled: Selective targeting of intracellular misfolded, pathogenic TDP-43 with rationally designed intrabodies.
  • Dr. Johanne Kaplan, ProMIS Chief Development Officer, will present the poster entitled: Conformational epitopes exposed on misfolded toxic forms of amyloid-beta, tau and alpha-synuclein directly contribute to their seeding activity.
  • Both presentations will be available on the ProMIS website ( www.promisneurosciences.com ) after the AAIC closes on July 30.

Orion’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality Therapy

Retrieved on: 
Wednesday, June 9, 2021
Pain, Medicine, Branches of biology, Nociception, Pain management, Health informatics, Acute pain, Pain scale, Chronic pain, Cognitive behavioral therapy, Promis, SAMD

Non-statistically significant improvements were reported with DTxP for Oswestry Disability Index (ODI), pain interference (Patient-Reported Outcomes Information System: PROMIS), and pain intensity (PROMIS-Numerical Rating Scale).

Key Points: 
  • Non-statistically significant improvements were reported with DTxP for Oswestry Disability Index (ODI), pain interference (Patient-Reported Outcomes Information System: PROMIS), and pain intensity (PROMIS-Numerical Rating Scale).
  • Cognitive Behavioral Therapy (CBT) is scientifically sound, effective and a recommended method to improve the self-management of chronic pain.
  • Orion is looking for a partner to further develop and commercialise Orions digital therapeutics software solution for Chronic Pain.
  • Orions DTxP, aimed to be a software as medical device (SaMD), is built for virtual reality (VR) devices to provide an immersive gamified therapeutic treatment program for the chronic pain patients.

ProMIS Neurosciences appoints renowned scientist, Dr. David Wishart as Chief Physics Officer

Retrieved on: 
Thursday, May 27, 2021
Intrabody, Alzheimer's disease, Neurodegenerative disorders, Neurological disorders, Structural proteins, Promis, Protein aggregation, Promis, Branches of biology

ProMIS has leveraged its industry leading technology platform to create a portfolio of antibody, intrabody and vaccine candidates that are highly selective for the misfolded protein aggregates driving pathogenesis, stated Dr. Neil Cashman, ProMIS Chief Scientific Officer (CSO).

Key Points: 
  • ProMIS has leveraged its industry leading technology platform to create a portfolio of antibody, intrabody and vaccine candidates that are highly selective for the misfolded protein aggregates driving pathogenesis, stated Dr. Neil Cashman, ProMIS Chief Scientific Officer (CSO).
  • As Chief Physics Officer, Dr. Wishart will play a pivotal role to further develop and expand the application of our proprietary platform to the biology of additional misfolded protein diseases.
  • I would also like to take this opportunity to sincerely thank Dr. Steven Plotkin for his outstanding prior service to the company as the ProMIS Chief Physics Officer since its inception.
  • ProMISs unique capability is our unrivalled antibody discovery platform, and Dr. Wishart has already added immeasurably to that capability, said Executive Chairman Eugene Williams.

ProMIS Neurosciences Announces First Quarter 2021 Results

Retrieved on: 
Friday, May 14, 2021
Finance, Corporate finance, Debenture, Debt, Biogen, Promis, Grundman, Money, Life sciences

ProMIS Neurosciences has a unique antibody design capability, which not even the largest pharmaceutical companies have to the best of our knowledge based on ongoing discussions with them.

Key Points: 
  • ProMIS Neurosciences has a unique antibody design capability, which not even the largest pharmaceutical companies have to the best of our knowledge based on ongoing discussions with them.
  • In the Alzheimer\xe2\x80\x99s field, positive results or regulatory steps were announced by Lilly, Cassava, and Biogen, all of which support the science suggesting PMN310 may be \xe2\x80\x9cbest in class\xe2\x80\x9d.\nIn January 2021, we announced an outline of our strategic priorities and action plan for 2021.
  • Both these events have positive implications for PMN310.\nIn March 2021, we completed a US$7.0 million (CDN$8.75 million) private placement of unsecured convertible debentures (Debentures).
  • Dr. Grundman is Professor of Neurosciences at the University of California San Diego (UCSD).

ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing with Distinguished Group of Boston Based Investors

Retrieved on: 
Monday, March 22, 2021
Fenway Sports Group, Liverpool F.C., Michael Gordon, Promis, Promis

The investors include Mike Gordon of Fenway Sports Group, the Kraft Group, Henry McCance, co-founder of the Cure Alzheimers Fund, and Jeremy Sclar of WS Development Group.

Key Points: 
  • The investors include Mike Gordon of Fenway Sports Group, the Kraft Group, Henry McCance, co-founder of the Cure Alzheimers Fund, and Jeremy Sclar of WS Development Group.
  • Our group is pleased to provide funding for the next phase of the company's exciting future, stated Mike Gordon of Fenway Sports Group.
  • We are honored to have the support of such a distinguished group of investors, all of whom are accomplished leaders in the business and life sciences arenas, said Gene Williams, ProMIS Executive Chairman.
  • ProMIS Neurosciences was launched six years ago based on a world class scientific platform from our CSO and scientific founder, Dr. Neil Cashman.

ProMIS Neurosciences Offers Perspectives on Recent Progress in the Alzheimer’s/Amyloid Field

Retrieved on: 
Tuesday, February 2, 2021
Monoclonal antibodies, Branches of biology, Aducanumab, Promis, Alzheimer's disease, Promis, Neuroscience, Psychiatry

Two important events occurred in January 2021, both of which we consider very positive for the Alzheimers field, for the updated amyloid hypothesis, and for ProMIS Neurosciences.

Key Points: 
  • Two important events occurred in January 2021, both of which we consider very positive for the Alzheimers field, for the updated amyloid hypothesis, and for ProMIS Neurosciences.
  • Both these events have positive implications for ProMIS and PMN310, ProMIS lead antibody therapeutic candidate for AD.
  • It appears that prediction was correct, stated Eugene Williams, Executive Chairman of ProMIS Neurosciences.
  • In line with this assessment, we believe the FDA will issue an approval of aducanumab in the summer of 2021.

ProMIS Neurosciences Closes First Tranche of Private Placement

Retrieved on: 
Thursday, November 5, 2020
Medical specialties, Branches of biology, Microsoft Windows, Vaccination, Protein folding, Promis, Vaccine, Proteopathy, Spotify, Antibody

A second closing (the Final Closing) of the Offering is expected to be completed within a week.

Key Points: 
  • A second closing (the Final Closing) of the Offering is expected to be completed within a week.
  • ProMIS proprietary peptide antigens can also be used to create potential therapeutic antibodies, as well as serve as the basis for development of vaccines.
  • ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
  • To learn more about protein misfolding diseases, listen to Episodes 11, 24, of Saving Minds, a podcast available at iTunes or Spotify.

ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 22nd Annual Investment Conference

Retrieved on: 
Thursday, September 10, 2020
Promis, OTC Markets Group, Promis, Webcast, Telecommunications, Mass media, Service industries

ProMIS Executive Chairman, Eugene Williams, will provide an update on the Company with special focus on the opportunities to detect, treat and ultimately prevent Alzheimers disease.

Key Points: 
  • ProMIS Executive Chairman, Eugene Williams, will provide an update on the Company with special focus on the opportunities to detect, treat and ultimately prevent Alzheimers disease.
  • Mr. Williams webcast presentation is scheduled for Tuesday, September 15, 2020 at 1:00 pm ET.
  • The webcast will be available live and approximately 24 hours following the live presentation through the following link here and on the Companys website .
  • ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

ProMIS Neurosciences and BC Neuroimmunology announce revenue-sharing joint venture agreement to develop and offer blood-based diagnostic tests for Alzheimer’s disease

Retrieved on: 
Thursday, July 9, 2020
Branches of biology, Medicine, Clinical medicine, Biomarkers, Cognitive disorders, Psychiatric diagnosis, Cell biology, Alzheimer's disease, Promis

The progress this year in measuring P-tau181 in the blood marks an inflection point in the fight against Alzheimers disease, stated Eugene Williams, ProMIS Executive Chairman.

Key Points: 
  • The progress this year in measuring P-tau181 in the blood marks an inflection point in the fight against Alzheimers disease, stated Eugene Williams, ProMIS Executive Chairman.
  • We now have blood-based biomarkers that can provide the information necessary to detect Alzheimers disease, including pre-symptomatic disease.
  • Further assays will be added subsequently, potentially incorporating ProMIS proprietary peptide antigens and tests for additional neurodegenerative diseases.
  • To learn more about diagnostic testing for Alzheimers disease, listen to Episode 26 of the podcast, Saving Minds, available at iTunes or on ProMIS Neurosciences website.

ProMIS Neurosciences announces adjournment and change of location of annual meeting of shareholders

Retrieved on: 
Wednesday, June 24, 2020
OTC Markets Group, Promis, Promis, Proxy

Shareholders are reminded to submit their votes by proxy before the extended proxy deadline of 9:00 a.m. (Pacific Time) on Monday, July 27th, 2020.

Key Points: 
  • Shareholders are reminded to submit their votes by proxy before the extended proxy deadline of 9:00 a.m. (Pacific Time) on Monday, July 27th, 2020.
  • Shareholders may choose to attend the meeting by teleconference, but will not be able to vote via teleconference.
  • Using this unique, precision approach, ProMIS is developing novel antibody therapeutics for AD, ALS and PD.
  • ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.